[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3494116T3 - Modulatory receptora estrogenowego - Google Patents

Modulatory receptora estrogenowego

Info

Publication number
PL3494116T3
PL3494116T3 PL18705097T PL18705097T PL3494116T3 PL 3494116 T3 PL3494116 T3 PL 3494116T3 PL 18705097 T PL18705097 T PL 18705097T PL 18705097 T PL18705097 T PL 18705097T PL 3494116 T3 PL3494116 T3 PL 3494116T3
Authority
PL
Poland
Prior art keywords
estrogen receptor
receptor modulators
modulators
estrogen
receptor
Prior art date
Application number
PL18705097T
Other languages
English (en)
Inventor
James Stewart Scott
Thomas Andrew MOSS
Samantha Jayne HUGHES
Johannes Wilhelmus Maria Nissink
Bernard Christophe Barlaam
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL3494116T3 publication Critical patent/PL3494116T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL18705097T 2017-01-30 2018-01-29 Modulatory receptora estrogenowego PL3494116T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762451971P 2017-01-30 2017-01-30
US201762523695P 2017-06-22 2017-06-22
US201762560304P 2017-09-19 2017-09-19
US201762592485P 2017-11-30 2017-11-30
EP18705097.6A EP3494116B1 (en) 2017-01-30 2018-01-29 Estrogen receptor modulators
PCT/EP2018/052040 WO2018138303A1 (en) 2017-01-30 2018-01-29 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
PL3494116T3 true PL3494116T3 (pl) 2020-04-30

Family

ID=61223883

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18705097T PL3494116T3 (pl) 2017-01-30 2018-01-29 Modulatory receptora estrogenowego

Country Status (37)

Country Link
US (3) US10221173B2 (pl)
EP (2) EP3689873B1 (pl)
JP (1) JP6951451B2 (pl)
KR (1) KR102246668B1 (pl)
CN (1) CN110214140B (pl)
AU (1) AU2018211495B2 (pl)
BR (1) BR112019015389A2 (pl)
CA (1) CA3050337A1 (pl)
CL (1) CL2019001991A1 (pl)
CO (1) CO2019008941A2 (pl)
CR (1) CR20190379A (pl)
CY (1) CY1122731T1 (pl)
DK (1) DK3494116T3 (pl)
DO (1) DOP2019000183A (pl)
EC (1) ECSP19062381A (pl)
ES (2) ES2931320T3 (pl)
HU (1) HUE047761T2 (pl)
IL (1) IL268263B (pl)
JO (1) JOP20190183B1 (pl)
LT (1) LT3494116T (pl)
MA (1) MA52555A (pl)
MX (1) MX2019008438A (pl)
MY (1) MY196317A (pl)
NI (1) NI201900080A (pl)
PE (1) PE20191500A1 (pl)
PH (1) PH12019501724A1 (pl)
PL (1) PL3494116T3 (pl)
PT (1) PT3494116T (pl)
RS (1) RS59770B1 (pl)
SG (1) SG11201906767XA (pl)
SI (1) SI3494116T1 (pl)
SM (1) SMT202000010T1 (pl)
TN (1) TN2020000009A1 (pl)
TW (1) TWI794205B (pl)
UA (1) UA125043C2 (pl)
WO (1) WO2018138303A1 (pl)
ZA (1) ZA201904696B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015419B1 (pt) 2016-02-05 2024-01-30 Inventisbio Llc Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica
ES2922379T3 (es) 2016-12-16 2022-09-14 Janssen Pharmaceutica Nv Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
WO2021055749A1 (en) * 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates
CN115557920B (zh) * 2022-09-22 2024-02-20 吉林奥来德光电材料股份有限公司 一种发光辅助材料、其制备方法及有机电致发光器件

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US7541354B2 (en) 2000-08-10 2009-06-02 Pfizer Italia S.R.L. Bicyclo-pyrazoles
WO2005111208A1 (ja) * 2004-04-27 2005-11-24 Chugai Seiyaku Kabushiki Kaisha プラズマ細胞の増殖方法
TW200716628A (en) 2005-03-22 2007-05-01 Astrazeneca Ab Novel compounds
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2010138659A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
TWI574961B (zh) 2009-05-27 2017-03-21 Ptc治療公司 治療癌症及非腫瘤病症之方法
US20120157401A1 (en) * 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
JP2015500346A (ja) 2011-12-14 2015-01-05 セラゴン ファーマシューティカルズ,インク. エストロゲン受容体モジュレーターおよびその使用
SI3004090T1 (en) * 2013-05-28 2018-01-31 Astrazeneca Ab Chemical compounds
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
SG11201509508YA (en) 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
US20160175284A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
CN118005631A (zh) * 2014-12-18 2024-05-10 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
AU2016279330B2 (en) 2015-06-16 2020-05-14 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
PL3355884T3 (pl) 2015-10-01 2021-11-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pirydo[3,4-b]indolowe leki antyestrogenowe
JP6920295B2 (ja) 2015-11-09 2021-08-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
WO2017080338A1 (zh) 2015-11-12 2017-05-18 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
EP3395809A4 (en) 2015-12-22 2019-06-19 Jiangsu Hengrui Medicine Co. Ltd. BENZOPIPERIDIN DERIVATIVE, PRODUCTION METHOD AND MEDICAL USE THEREOF
US9969732B2 (en) 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
WO2017182493A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
WO2017192991A1 (en) 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
CN109415361B (zh) 2016-06-29 2022-03-08 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
TW201815789A (zh) * 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
ES2975558T3 (es) 2016-09-15 2024-07-09 Arvinas Inc Derivados de indol como degradantes de receptor de estrógeno
PE20191078A1 (es) 2016-10-24 2019-08-20 Astrazeneca Ab Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina utiles en el tratamiento del cancer
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
UA122035C2 (uk) 2016-12-16 2020-08-25 Пфайзер Інк. Агоністи рецептора glp-1 та їх застосування
ES2922379T3 (es) 2016-12-16 2022-09-14 Janssen Pharmaceutica Nv Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
JP2020502117A (ja) 2016-12-16 2020-01-23 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 殺生物剤化合物
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
NZ754115A (en) 2016-12-16 2021-07-30 Lilly Co Eli 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
MX2019008895A (es) 2017-01-30 2019-09-13 Chiesi Farm Spa Derivados de amida de tirosina como inhibidores de rho-cinasa.

Also Published As

Publication number Publication date
WO2018138303A1 (en) 2018-08-02
ES2931320T3 (es) 2022-12-28
AU2018211495A1 (en) 2019-09-12
SMT202000010T1 (it) 2020-03-13
ES2766249T3 (es) 2020-06-12
MY196317A (en) 2023-03-24
CN110214140B (zh) 2022-08-30
EP3689873B1 (en) 2022-09-14
US10221173B2 (en) 2019-03-05
US10590132B2 (en) 2020-03-17
CY1122731T1 (el) 2021-05-05
CN110214140A (zh) 2019-09-06
TWI794205B (zh) 2023-03-01
LT3494116T (lt) 2020-01-10
AU2018211495B2 (en) 2020-05-21
DK3494116T3 (da) 2020-01-27
CR20190379A (es) 2019-10-21
JOP20190183B1 (ar) 2022-09-15
SI3494116T1 (sl) 2020-02-28
EP3494116B1 (en) 2019-10-23
CO2019008941A2 (es) 2019-08-30
ECSP19062381A (es) 2019-09-30
DOP2019000183A (es) 2019-07-31
JOP20190183A1 (ar) 2019-07-28
MA52555A (fr) 2021-03-17
PE20191500A1 (es) 2019-10-22
IL268263B (en) 2021-10-31
HUE047761T2 (hu) 2020-05-28
BR112019015389A2 (pt) 2020-03-10
MX2019008438A (es) 2019-10-30
JP6951451B2 (ja) 2021-10-20
CA3050337A1 (en) 2018-08-02
TW201840558A (zh) 2018-11-16
NI201900080A (es) 2020-03-18
KR20190112767A (ko) 2019-10-07
ZA201904696B (en) 2020-05-27
EP3689873A1 (en) 2020-08-05
CL2019001991A1 (es) 2019-10-11
EP3494116A1 (en) 2019-06-12
US20190233413A1 (en) 2019-08-01
PT3494116T (pt) 2020-01-28
JP2020505354A (ja) 2020-02-20
UA125043C2 (uk) 2021-12-29
TN2020000009A1 (en) 2021-10-04
US20200239468A1 (en) 2020-07-30
US20180282325A1 (en) 2018-10-04
RS59770B1 (sr) 2020-02-28
KR102246668B1 (ko) 2021-04-29
US11046689B2 (en) 2021-06-29
IL268263A (en) 2019-09-26
SG11201906767XA (en) 2019-08-27
PH12019501724A1 (en) 2020-06-01

Similar Documents

Publication Publication Date Title
IL285318A (en) Estrogen receptor modulators
HK1247199A1 (zh) 雌激素受體調節劑及其用途
HK1253558A1 (zh) 法尼醇x受體調節劑
ZA201605712B (en) Therapeutic combinations with estrogen receptor modulators
HK1248683A1 (zh) 雜環雌激素受體調節劑及其用途
IL268319A (en) Benzothiophene estrogen receptor modulators
SG11201606876RA (en) Toll like receptor modulator compounds
IL286107A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL274537A (en) nuclear receptor modulators
HK1258851A1 (zh) 四氫萘雌激素受體調節劑及其用途
IL268263B (en) Estrogen receptor modulators
GB201702617D0 (en) Receptor
GB201716468D0 (en) Modulators
ZA201904333B (en) Adenosine a3 receptor modulators
EP3224230A4 (en) Estrogen receptor modulators
EP3463342A4 (en) ASSOCIATIONS OF ESTROGEN RECEPTOR MODULATORS
GB2563095B (en) Modulators
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
GB201616065D0 (en) Receptor modulator compounds
GB201616072D0 (en) Receptor modulator compounds
GB201616071D0 (en) Receptor modulator compounds
GB201702926D0 (en) Modulators
GB201603861D0 (en) Receptor modulation
GB201512714D0 (en) Receptor modulator compounds